On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients.
D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001479:Basal Ganglia / Q000187:drug effects* / Q000378:metabolism; D001593:Benzyl Compounds / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists; D006834:Hydrazines / Q000494:pharmacology; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D011732:Pyridoxal Phosphate / Q000378:metabolism; D011736:Pyridoxine / Q000494:pharmacology*; D051381:Rats; D012694:Serine / Q000494:pharmacology
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001593:Benzyl Compounds; D018492:Dopamine Antagonists; D006834:Hydrazines; D012694:Serine; D011732:Pyridoxal Phosphate; D004295:Dihydroxyphenylalanine; D011736:Pyridoxine; D004298:Dopamine